Drugs / Y-90 FAPI
Y-90 FAPI
also known as
90Y-FAPI · FAPI · Y-90 FAPI Radioligand Therapy · Y-90-labeled FAPI · Yttrium-90-labeled FAPI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07500285 | Apr 2026 → Jun 2027 expected | non-small cell lung carcinoma | Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization | Not yet recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-90 FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500285 ↗ |
| Known as | 90Y-FAPI | “All enrolled participants will receive Yttrium-90-labeled FAPI (90Y-FAPI) administered intravenously according to the study protocol.” NCT07500285 ↗ |
| Known as | FAPI | “Yttrium-90-labeled Fibroblast Activation Protein inhibitor (Y-90 FAPI) administered intravenously as targeted radionuclide therapy in patients with chemotherapy-resistant...” NCT07500285 ↗ |
| Known as | Y-90 FAPI Radioligand Therapy | “Y-90 FAPI Radioligand Therapy” NCT07500285 ↗ |
| Known as | Y-90-labeled FAPI | “Y-90-labeled FAPI” NCT07500285 ↗ |
| Known as | Yttrium-90-labeled FAPI | “All enrolled participants will receive Yttrium-90-labeled FAPI (90Y-FAPI) administered intravenously according to the study protocol.” NCT07500285 ↗ |
| Action | Inhibit | “Fibroblast Activation Protein inhibitor” NCT07500285 ↗ |
| Modality | Other / unclassified | “targeted radionuclide therapy” NCT07500285 ↗ |
| Route | Intravenous | “administered intravenously” NCT07500285 ↗ |